332 related articles for article (PubMed ID: 8814852)
1. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of sex hormone levels and risk of prostate cancer.
Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
[TBL] [Abstract][Full Text] [Related]
3. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
[TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
5. Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone.
Klaassen Z; Howard LE; Moreira DM; Andriole GL; Terris MK; Freedland SJ
Prostate; 2017 Apr; 77(5):466-470. PubMed ID: 27990661
[TBL] [Abstract][Full Text] [Related]
6. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
7. Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys.
Kim MR; Gupta MK; Travers SH; Rogers DG; Van Lente F; Faiman C
Clin Endocrinol (Oxf); 1999 Feb; 50(2):203-10. PubMed ID: 10396363
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
[TBL] [Abstract][Full Text] [Related]
9. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
[TBL] [Abstract][Full Text] [Related]
10. Vasectomy and prostate cancer: results from a multiethnic case-control study.
John EM; Whittemore AS; Wu AH; Kolonel LN; Hislop TG; Howe GR; West DW; Hankin J; Dreon DM; Teh CZ
J Natl Cancer Inst; 1995 May; 87(9):662-9. PubMed ID: 7538594
[TBL] [Abstract][Full Text] [Related]
11. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
Lerner SE; Jacobsen SJ; Lilja H; Bergstralh EJ; Ransom J; Klee GG; Piironen T; Blute ML; Lieber MM; Zincke H; Pettersson K; Peterson D; Oesterling JE
Urology; 1996 Aug; 48(2):240-8. PubMed ID: 8753736
[TBL] [Abstract][Full Text] [Related]
12. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
13. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
Schnoeller T; Jentzmik F; Rinnab L; Cronauer MV; Damjanoski I; Zengerling F; Ghazal AA; Schrader M; Schrader AJ
World J Urol; 2013 Apr; 31(2):253-9. PubMed ID: 22763628
[TBL] [Abstract][Full Text] [Related]
14. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
[TBL] [Abstract][Full Text] [Related]
15. Study on the binding of dihydrotestosterone, testosterone and oestradiol with sex hormone binding globulin.
Mean F; Pellaton M; Magrini G
Clin Chim Acta; 1977 Oct; 80(1):171-80. PubMed ID: 561671
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
17. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Morita S; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
BMC Cancer; 2014 Sep; 14():717. PubMed ID: 25256077
[TBL] [Abstract][Full Text] [Related]
18. Serum androgens and prostate-specific antigen levels in androgenetic alopecia: is there a difference between frontal and vertex baldness?
Lis-Święty A; Arasiewicz H; Ranosz-Janicka I; Brzezińska-Wcisło L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1815-1818. PubMed ID: 29237093
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trend in Androgen Status and Androgen-Sensitive Outcomes in Older Men.
Hsu B; Cumming RG; Hirani V; Blyth FM; Naganathan V; Le Couteur DG; Seibel MJ; Waite LM; Handelsman DJ
J Clin Endocrinol Metab; 2016 Apr; 101(4):1836-46. PubMed ID: 26918290
[TBL] [Abstract][Full Text] [Related]
20. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
